Ultragenyx's setrusumab fails Phase 3 primary endpoints in OI; expense cuts planned

Ultragenyx Pharmaceutical Inc.

Orbit and Cosmic studies did not meet primary endpoint of reducing annualized clinical fracture rate versus comparators.
Both studies achieved secondary endpoint of significant improvement in bone mineral density (BMD).
Company plans to implement significant expense reductions; evaluating next steps for the program.
Safety profile unchanged; no new safety signals observed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.